Chief Executive Pascal Soriot of British pharmaceutical company AstraZeneca Plc (STO:AZN)(LON:AZN) said that the company is still waiting for the go-ahead from the US drug regulator, the Federal Drug Administration (FDA), to restart the clinical trial of its potential COVID-19 vaccine in the US, Reuters news agency reported on Thursday.
Reportedly, the US trial of AstraZeneca's COVID-19 vaccine candidate, initially developed by the University of Oxford, remains on hold while regulators investigate an illness in one of the participants, even after a British study and other programmes outside of the US have resumed.
According to US Health and Human Services Secretary Alex Azar, this continued suspension showed the US FDA took vaccine safety seriously.
Oxford University has stated the illness in a British participant that triggered the trail pause on 6 September 2020 may not have been associated with the vaccine, Reuters added.
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML
Ligand Pharmaceuticals announces presentation of Captisol-enabled Topiramate Injection data